Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02146755
Other study ID # 013-178
Secondary ID
Status Completed
Phase N/A
First received April 10, 2014
Last updated June 9, 2017
Start date August 2013
Est. completion date December 2015

Study information

Verified date June 2017
Source Baylor Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aortic stenosis is a common valvular heart disease, affecting mainly people over age 60. It is characterized by years to decades of slow progression followed by rapid clinical deterioration and a high death rate once symptoms develop. The onset of symptoms confers a poor prognosis: patients die within an average of five years after the onset of angina, three years after the onset of syncope, and two years after the onset of heart failure symptoms. The overall mortality rate is 75% at three years without surgery. Drug therapy for it remains ineffective, and aortic valve replacement is the only recommended long-term treatment.


Description:

OBJECTIVES Primary Objective The primary objective of this study is to review the current practice of transthoracic echocardiogram (TTE) imaging measurements in conjunction with computerized tomography (CT) and to standardize these measurements in order to improve the accuracy of the diagnosis of aortic stenosis (AS).

Secondary Objective The secondary objective of the study is to define the true incidence of low flow, low gradient severe aortic stenosis with a normal ejection fraction (EF).

BACKGROUND In recent years, the advancement of medical technology has allowed certain patients to undergo less invasive approaches for aortic valve replacement such as transcatheter aortic valve replacement (TAVR). In order to appropriately select treatment options, anatomical measurements must be accurately obtained utilizing TTE and CT.

According to the American College of Cardiology/American Heart Association Practice Guidelines, the severity o f aortic stenosis is determined by definitions of aortic jet velocity, mean pressure gradient, and aortic valve area (AVA) (Bonow, 2008).

Mild Moderate Severe AVA (cm2) 1.5 1.0 - 1.5 < 1.0 Mean gradient (mmHg) < 25 25 - 40 > 40 Jet velocity (m/s) < 3.0 3.0 - 4.0 > 4.0

Rationale for study

Of greatest interest to this study is the calculation of the AVA in the diagnosis of the severity of aortic stenosis. Since the area cannot be directly measured from echocardiographic images, it is calculated based on the diameter across the left ventricular outflow tract (LVOT) as measured via TTE. The preferred modality for measuring AVA is the continuity equation:

AVA=((〖Area〗_LVOT ×〖VTI〗_LVOT))/〖VTI〗_AS Where LVOT = Left Ventricular Outflow Tract, VTI = Doppler velocity-time interval.

Using TTE, the stroke volume at the LVOT is obtained by measuring the diameter across the LVOT. The continuity equation assumes the aortic valve annulus is a perfect circle; because of this, any error in measuring the LVOT results in an under calculation of the aortic valve area. It is also important to consider that the anatomy of the aortic annulus is not circular, which also contributes to an inaccurate calculated AVA.

An underestimated valve area could lead to a diagnosis of severe aortic stenosis when not appropriate. Recently, there has been an increase in literature published on the diagnosis of severe aortic stenosis with a low mean gradient and preserved left ventricular function as measured by ejection fraction (EF). It is possible that many of these patients do not have severe AS but are misclassified as such because underestimation of the LVOT diameter leads to underestimation of aortic valve area as calculated by the continuity equation. This study aims to define the true incidence of these patients by ensuring the aortic valve area is measured as accurately as possible based on current imaging procedures.

In order to determine the accuracy of TTE measurements in current practice, this study would compare the LVOT diameter from TTE to the LVOT diameter on CT scans, which is inherently three-dimensional and therefore more accurate.

The AVA of all subjects will be re-calculated using the continuity equation and the LVOT diameter measured with CT. These re-calculated AVA will be compared to the original AVA obtained via TTE. In subjects whose newly calculated AVA, utilizing CT measurements, varies greatly from their TTE calculated AVA, the original TTE images will be re-evaluated for correct measurements. Additionally, any subject with a TTE-measured LVOT diameter less than 2 cm will also be re-evaluated for correct measurement.

The figure below illustrates an underestimated LVOT diameter using 2D echocardiography.

Anumeha Tandon, Paul A. Grayburn, Imaging of Low-Gradient Severe Aortic Stenosis, JACC: Cardiovascular Imaging, Volume 6, Issue 2, February 2013, Pages 184-195, ISSN 1936-878X, http://dx.doi.org/10.1016/j.jcmg.2012.11.005.

(http://www.sciencedirect.com/science/article/pii/S1936878X12009497)

PATIENT POPULATION

This study is an observational, retrospective review of data collected as standard of care. The study intends to review the charts of up to 400 patients over the last 5 years who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center (BUMC).

SUMMARY Enrollment Up to 400 patients at THHBP and BUMC Design This study is a retrospective chart review of previously collected standard of care data.

METHODS, STATISTICAL ANALYSIS & DATA MANAGEMENT Patients will be classified as severe or non-severe AS based on aortic valve area calculation as per ACC/AHA guidelines. Thus, patients with AVA ≤ 1.0 cm2 will be considered severe AS. This will also be evaluated using two other widely used criteria for aortic valve area indexed for body surface area. Severe AS will be considered as AVAi ≤ 0.6 cm2 (guidelines) or ≤ 0.5 cm2 (Braunwald's text, Grayburn). Using these three definitions, any patient who also has a peak velocity ≥ 4.0 m/s or a mean gradient ≥ 40 mmHg will be considered to definitely have severe AS. Patients with values < 4.0 m/s or < 50 mmHg will be further classified by stroke volume index < 35 mL/m2 to have low flow, low gradient severe AS. Further classification will be based on LVEF ≥ 50% or <50%. The former will be considered to have paradoxical low flow, low gradient severe AS with preserved LVEF (Hachicha, Circ 2007) or traditional low flow, low gradient severe AS (Tandon, Grayburn JACC Imaging 20130> The above criteria will be used to reclassify patients when LVOT cross-sectional area is determined by CT scan instead of echocardiography. Reclassification will occur with CT measurements of LVOT for AVA and SVI, both of which are dependent on LVOT area, generalized linear mixed model (GLMM) with a logistic link function will be used to assess whether differences in classification exist.

The same multivariable model stratified by gender will be used to perform a pre-specified subgroup analysis (re-measuring the echocardiographic LVOT diameter on all subjects who are "re-classified" by CT). This will be done by remeasuring at the traditional LVOT diameter located 5-10 mm below the aortic annulus and also by measuring at the juncture of the aortic leaflets and LVOT in mid-systole (Mayo clinic way). The purpose of this analysis is to determine if the Mayo clinic method of LVOT measurement reduces the number of misclassifications compared to the traditional method. Finally, the investigators will also examine the CT data for threshold values which suggest erroneous or outlier values for echocardiography. Men and women will be assessed separately. For example, a value of 1.6 cm is often found on echocardiography but rarely on CT scanning in their subjective clinical experience.


Recruitment information / eligibility

Status Completed
Enrollment 396
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

- Adults over the age of 18.

- Any patient undergoing both TTE and CT scans within a one-week timeframe as a workup for aortic stenosis.

Exclusion Criteria

- There are no specific exclusion criteria for this retrospective review.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Baylor University Medical Center at Dallas Dallas Texas
United States Heart Hospital Baylor Plano Plano Texas

Sponsors (1)

Lead Sponsor Collaborator
Baylor Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reclassification of patients based on CT measurements of LVOT for AVA and SVI. Echocardiography assessments of Aortic stenosis are technician dependent and can vary while CT evaluations are consistent and do not vary by user. This study will retrospectively examine subjects that have undergone both assessments as a workup for definitive aortic valve treatment. The anatomical measurements obtained from CT will be used to recalculate Aortic Valve Area utilizing the standard formulas and gradients/velocities obtained from echocardiography. Patients will be reclassified appropriately into "severe and non-severe" AS according to the new calculations. The results of this will be analyzed to establish standardized ranges for measurements to prevent over or under measuring aortic valve anatomy during these tests (Echo and CT). Baseline
See also
  Status Clinical Trial Phase
Completed NCT03186339 - Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Completed NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease